Published in Vaccine Weekly, January 31st, 2001
"Few cases of anti-colon cancer specific T lymphocytes have been described so far," wrote A.J.A. Bremers and colleagues, Institute Nazional Studio & Cura Tumori, Unit Immunotherapy Human Tumors. "Moreover, the majority of these effectors were generated in vitro by stimulating peripheral blood mononuclear cells (PBMC) from patients or healthy donors with peptides that were derived from proteins expressed and/or secreted by colon cancer tissue such as CEA, Mucin or Her-2/neu. The aim of our study was to evaluate the immunogenicity of colorectal carcinomas in an autologous...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.